An animal model of chronic inflammatory pain: Pharmacological and temporal differentiation from acute models

被引:64
作者
Wilson, Alex W.
Medhurst, Stephen J.
Dixon, Claire I.
Bontoft, Nick C.
Winyard, Lisa A.
Brackenborough, Kim T.
De Alba, Jorge
Clarke, Christopher J.
Gunthorpe, Martin J.
Hicks, Gareth A.
Bountra, Chas
McQueen, Daniel S.
Chessell, Lain P.
机构
[1] GlaxoSmithKline Res & Dev Ltd, Neurol & Gastrointestinal CEDD, Dept Pain Res, Harlow CM19 5AW, Essex, England
[2] Univ Edinburgh, Coll Med & Vet Med, Div Neurosci, Edinburgh EH8 9JZ, Midlothian, Scotland
关键词
chronic inflammation pain; hypersensitivity; NR2B antagonist; iNOS inhibitor; joint;
D O I
10.1016/j.ejpain.2005.08.003
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Clinically, inflammatory pain is far more persistent than that typically modelled pre-clinically, with the majority of animal models focussing on short-term effects of the inflammatory pain response. The large attrition rate of compounds in the clinic which show pre-clinical efficacy suggests the need for novel models of, or approaches to, chronic inflammatory pain if novel mechanisms are to make it to the market. A model in which a more chronic inflammatory hypersensitivity phenotype is profiled may allow for a more clinically predictive tool. The aims of these studies were to characterise and validate a chronic model of inflammatory pain. We have shown that injection of a large volume of adjuvant to the intra-articular space of the rat knee results in a prolonged inflammatory pain response, compared to the response in an acute adjuvant model. Additionally, this model also results in a hypersensitive state in the presence and absence of inflammation. A range of clinically effective analgesics demonstrate activity in this chronic model, including morphine (3 mg/kg, t.i.d.), dexamethasone (1 mg/kg, b.i.d.), ibuprofen (30 mg/kg, t.i.d.), etoricoxib (5 mg/kg, b.i.d.) and rofecoxib (0.3-10 mg/kg, b.i.d.). A further aim was to exemplify the utility of this chronic model over the more acute intra-plantar adjuvant model using two novel therapeutic approaches; NR2B selective NMDA receptor antagonism and NOS inhibition. Our data shows that different effects were observed with these therapies when comparing the acute model with the model of chronic inflammatory joint pain. These data suggest that the chronic model may be more relevant to identifying mechanisms for the treatment of chronic inflammatory pain states in the clinic. (C) 2005 European Federation of Chapters of the International Association for the Study of Pain. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:537 / 549
页数:13
相关论文
共 36 条
[1]  
[Anonymous], BRIT J PHARMACOL
[2]   BILATERAL CHANGES OF SUBSTANCE-P-LIKE, NEUROKININ-A-LIKE, CALCITONIN GENE-RELATED PEPTIDE-LIKE AND NEUROPEPTIDE-Y-LIKE IMMUNOREACTIVITY IN RAT KNEE-JOINT SYNOVIAL-FLUID DURING ACUTE MONOARTHRITIS [J].
BILEVICIUTE, I ;
LUNDEBERG, T ;
EKBLOM, A ;
THEODORSSON, E .
NEUROSCIENCE LETTERS, 1993, 153 (01) :37-40
[3]   Mechanisms of pain modulation in chronic syndromes [J].
Bolay, H ;
Moskowitz, MA .
NEUROLOGY, 2002, 59 (05) :S2-S7
[4]   Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: correlation with restricted localisation of NR2B subunit in dorsal horn [J].
Boyce, S ;
Wyatt, A ;
Webb, JK ;
O'Donnell, R ;
Mason, G ;
Rigby, M ;
Sirinathsinghji, D ;
Hill, RG ;
Rupniak, NMJ .
NEUROPHARMACOLOGY, 1999, 38 (05) :611-623
[5]   Endogenous peripheral antinociception in early inflammation is not limited by the number of opioid-containing leukocytes but by opioid receptor expression [J].
Brack, A ;
Rittner, HL ;
Machelska, H ;
Shaqura, M ;
Mousa, SA ;
Labuz, D ;
Zöllner, C ;
Schäfer, M ;
Stein, C .
PAIN, 2004, 108 (1-2) :67-75
[6]   QUANTITATIVE ASSESSMENT OF TACTILE ALLODYNIA IN THE RAT PAW [J].
CHAPLAN, SR ;
BACH, FW ;
POGREL, JW ;
CHUNG, JM ;
YAKSH, TL .
JOURNAL OF NEUROSCIENCE METHODS, 1994, 53 (01) :55-63
[7]  
Chazot P L, 2000, Curr Opin Investig Drugs, V1, P370
[8]   Orally efficacious NR2B-selective NMDA receptor antagonists [J].
Claiborne, CF ;
McCauley, JA ;
Libby, BE ;
Curtis, NR ;
Diggle, HJ ;
Kulagowski, JJ ;
Michelson, SR ;
Anderson, KD ;
Claremon, DA ;
Freidinger, RM ;
Bednar, RA ;
Mosser, SD ;
Gaul, SL ;
Connolly, TM ;
Condra, CL ;
Bednar, B ;
Stump, GL ;
Lynch, JJ ;
Macaulay, A ;
Wafford, KA ;
Koblan, KS ;
Liverton, NJ .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (04) :697-700
[9]  
COLPAERT FC, 1987, PAIN, V28, P210
[10]   Beneficial effects of GW274150, a novel, potent and selective inhibitor of NOS activity, in a rodent model of collagen-induced arthritis [J].
Cuzzocrea, S ;
Chatterjee, PK ;
Mazzon, E ;
McDonald, MC ;
Dugo, L ;
Di Paola, R ;
Serraino, I ;
Britti, D ;
Caputi, AP ;
Thiemermann, C .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2002, 453 (01) :119-129